A new clinical trial suggests that multiple doses of psilocybin, the active compound in “magic mushrooms,” may provide substantial relief for people suffering from obsessive-compulsive disorder. The results of this study indicate that repeated weekly treatments are safe and tend to significantly reduce the severity of obsessions and compulsive behaviors. This research https://doi.org/10.1177/02698811261424214” target=”_blank”>Psychopharmacology Journalprovides evidence of a new potential treatment avenue for people who have not had success with standard treatments.
Obsessive-compulsive disorder is a debilitating mental illness characterized by intrusive thoughts and repetitive behaviors. These symptoms can take a considerable amount of time and seriously interfere with daily life. Current standard treatment usually includes a combination of cognitive behavioral therapy and daily medications such as serotonin reuptake inhibitors.
However, these traditional approaches are often inadequate for many patients. Symptom relief is often delayed or incomplete, and adherence to treatment may be difficult due to unwanted side effects. Because of these challenges, scientists have sought alternative treatment approaches that can provide faster or more intense symptom relief.
Psilocybin has recently emerged as a promising candidate for treating a variety of psychiatric disorders. When ingested, the body converts it into psilocin, a chemical that binds to serotonin receptors in the brain. Scientists have observed that this substance tends to increase cognitive flexibility, which helps reduce the rigid thinking patterns characteristic of obsessive-compulsive disorder.
Brain imaging studies also suggest that psilocybin alters activity across specific neural networks associated with habitual responding and error monitoring. This particular circuit often functions abnormally in people with repetitive behavioral conditions. These observations provided a strong foundation for researchers to evaluate the safety and efficacy of compounds in a controlled clinical setting.
Francisco A. Moreno, a professor of psychiatry at the University of Arizona, explained that clinical observations inspired this line of research. “In the mid-1990s, I met a patient with treatment-resistant OCD who reported persistent OCD benefits while using hallucinogens,” Moreno said. “We wrote a case report in 1997 and a theoretical paper on a possible mechanism of action in 1998.”
Following these initial observations, the research team conducted initial tests to see if the substance was safe to administer. “We pursued and published a pilot study of different doses of psilocybin to intensively investigate safety and efficacy signals for OCD,” Moreno said. “This work was on hold for many years until we restarted this type of work a few years ago.”
To investigate this latest application, researchers recruited 15 adult participants between the ages of 18 and 65. All participants had a confirmed diagnosis of moderate to severe obsessive-compulsive disorder and had previously failed to respond to at least one standard treatment. Before the trial began, people taking psychiatric medications were required to gradually discontinue their use of the medication to ensure safety during psilocybin treatment.
The study was divided into two distinct phases of 4 weeks. In the first stage, participants were randomly assigned to one of three groups of five people. One group received weekly high doses of psilocybin, another group received low doses of psilocybin, and a third group received an active placebo called lorazepam, a common sedative.
This first step was double-blind, meaning neither the participants nor the researchers knew which substance was being administered. In the second phase of the trial, all 14 remaining participants received high doses of psilocybin once a week for four weeks. This phase was single-blind, meaning participants did not know exactly how much dose they were receiving.
Each treatment day required a 10-hour visit. Participants ingested capsules, wore eyeshades, and listened to a standardized music playlist. Two trained facilitators remained in the room to provide support, ensure safety, and guide participants back to a typical state of consciousness at the end of the session.
To track changes over time, the researchers used the Yale-Brown Obsessive-Compulsive Scale, a standard clinical interview used to measure the severity of a person’s symptoms. The scientists conducted these interviews before the study began, during each treatment, and periodically over the following weeks. They also monitored participants for signs of adverse side effects, suicidal thoughts, or psychosis.
Researchers found that repeated doses of psilocybin were generally well tolerated by participants. No serious adverse events or psychotic symptoms occurred, and there was no significant change in suicidal ideation. Although some participants experienced mild side effects, the most common problem reported during low-dose sessions was nausea.
In terms of symptom relief, high doses of psilocybin significantly reduced obsessive-compulsive symptoms during the first four weeks of the study. The day after the treatment session, those in the high-dose group had significantly lower symptom scores than the placebo group. This treatment effect remained stable even when measured a full week after the dosing session.
By the end of the entire 8-week program, the overall results were significant. After participants received at least four high doses of psilocybin, approximately 73 percent experienced at least a 35 percent reduction in symptom severity scores. Additionally, 40% of participants experienced complete remission of symptoms by the end of week 8.
The researchers also noticed a cumulative effect over the course of their study. A higher total number of psilocybin doses tended to predict greater overall reduction in obsessive-compulsive symptoms. When the researchers followed up the participants six months later, the reduction in symptoms decreased slightly, but most participants still saw significant relief.
This durable relief was a particularly noteworthy achievement for the research team. “We are pleased with the fact that most people who benefited from psilocybin remained in good condition six months later,” Moreno said.
“Many patients with OCD cannot benefit from current treatment options due to lack of efficacy, intolerance, access issues, and in some cases the disease itself, so it is highly desirable to have alternative options that can provide rapid and durable effects,” Moreno explained. “This study showed that psilocybin shows promise as a safe and effective option when used in a clinically controlled setting.”
Despite these promising results, this study has several limitations that provide context for the results. The most notable limitation is the small sample size of only 15 participants. This limited group size reduces the statistical power of the data and makes it difficult to generalize the results to the broader population.
The rigorous review process also limits the applicability of the results. “The safety findings in this study are the result of careful selection of treatment candidates and thoughtful protocols to protect participants,” Professor Moreno cautioned.
The intensive nature of the study, requiring long clinic visits and weekly travel, also placed a significant burden on participants. This requirement may have unintentionally selected highly motivated individuals with strong support systems, potentially skewing the results. Blinding in psychedelic trials is also notoriously difficult, as the intense psychoactive effects of high doses are difficult to mistake for calming placebos.
The use of low-dose groups and effective placebos has helped alleviate some of this blinding problem, but it remains a persistent challenge in psychedelic research. Another potential problem involved participants’ previous drug use. Exploratory data suggest that participants who recently discontinued serotonin treatment to participate in the study were less likely to respond to psilocybin treatment.
“Further research is needed in larger studies to demonstrate clinical utility,” Moreno noted. “We hope to replicate these findings in larger studies and work on dose discovery to determine the number of dosing sessions needed to achieve sustained effects.”
The research team is already planning next steps to better understand how this compound works. “We are conducting additional studies investigating mechanisms of action, functional imaging changes, and relationships with subjective experience,” Moreno said.
The study, “A Randomized Clinical Trial of Repeated Dose Psilocybin for the Treatment of Obsessive-Compulsive Disorder,” was authored by Francisco A. Moreno, Katja E. Allen, Christopher B. Wiegand, Rajan Dunn, James I. Prickett, Brian Bays, and John J.B. Allen.
